# Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

> **NCT01293669** · PHASE2 · COMPLETED · sponsor: **Targacept Inc.** · enrollment: 440 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TC-6987
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01293669
- **Lead sponsor:** Targacept Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2013-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01293669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01293669, "Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01293669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*